News

Tasquinimod works, says Phase II study
Enlarge image

BusinessSwedenFrance

Tasquinimod works, says Phase II study

05.06.2012 - Swedish Active Biotech draws new hope from a Phase II result with prostate cancer drug tasquinimod.

Lund – Almost a year ago Swedish Active Biotech AB saw its stock value dwindling away when the oral multiple sclerosis drug laquinimod failed in crucial Phase III testing. Although the price per share has doubled when compared to the start of the year, SEK44 is still far away from its last 12-month-cycle climax roughly a year ago.

On 4 June, Andrew Armstrong from the Duke Cancer Institute in Durham (USA) presented data on a long-term follow-up of a randomised Phase II placebo-controlled trial with Active Biotech's tasquinimod. The talk, given at the 2012 ASCO Annual Meeting in Chicago (USA), focussed on the median overall survival times of patients suffering from castrate resistant prostate cancer (CRPC) which increased from 30.4 months (placebo) to 33.4 months (tasquinimod). Armstrong expressed that these findings surprised him: "Men with metastatic CRPC in this trial were unexpectedly found to have prolonged survival times, despite a high fraction of patients with liver and lung metastases."  

Active Biotech is developing the drug together with Ipsen group, a pharmaceutical company from Paris (France) employing 4,500 people. Ipsen's CSO Claude Betrand was eager to announce he's pleased with the results: "We are thrilled. The results underline the activity of the compound. With its differentiated mechanism of action [not targeting the androgen receptor pathway] we hope to propose an alternative treatment after the ongoing Phase III results have replicated these interesting findings." So far 600 patients have been recruited for the double-blind Phase III study. In the end the study will include 1,200 patients from more than 250 clinics.

http://www.european-biotechnology-news.com/news/news/2012-02/tasquinimod-works-says-phase-ii-study.html

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

Events

All Events

Current issue

All issues

Product of the week

Products